Amedisys Inc. (Nasdaq: AMED) is awaiting a number of giant transactions to shut by the tip of the 12 months because it continues to develop its non-Medicare income and high-acute care enterprise considerably.

The corporate reported its second-quarter earnings outcomes on Wednesday, with out an accompanying earnings name. It has not held an official earnings name since UnitedHealth Group (NYSE: UNH) agreed to accumulate the corporate in June 2023, which is customary.

Residence well being revenues had been $377.4 million within the second quarter, up practically 8% year-over-year. Hospice revenues had been $204 million, up greater than 2% year-over-year.

Amedisys' non-Medicare house well being revenues grew considerably once more, to $161.3 million within the quarter, up 24% 12 months over 12 months.

Excessive-acuity care income, in the meantime, got here in at $9.8 million, up 145% year-over-year. Amedisys acquired Contessa Well being — a high-acuity house care supplier — in 2021 for $250 million. Admissions in that house had been up 57% year-over-year, in line with Amedisys. It now has 9 joint ventures contributing to its development, in addition to 33 referral hospitals.

In whole, Amedisys, based mostly in Baton Rouge, Louisiana, has 519 care facilities throughout 37 states and the District of Columbia.

It's been greater than a 12 months since UnitedHealth Group's Optum agreed to accumulate Amedisys for $3.3 billion. Amedisys lately agreed to promote a number of places to VitalCaring, the house well being care supplier led by April Anthony.

The divestment is contingent on the UnitedHealth Group-Amedisys deal going by way of. The divestment is probably going being executed to deal with antitrust considerations concerning the deal. Optum already owns LHC Group, one other of the nation's largest house well being care suppliers.